Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis
Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether el...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-04-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296211005555 |
| _version_ | 1819320332897484800 |
|---|---|
| author | Hafiz Abdul Waqas Ahmed MD Ahmed Taher Masoud MD Jia Han MD, PhD Ahmed Adel Sofy MD Ahmed Saeed Ahmed MD Ahmed Taha Abdesattart MD Emmanuel Kwateng Drokow MD, PhD Kai Sun MD, PhD |
| author_facet | Hafiz Abdul Waqas Ahmed MD Ahmed Taher Masoud MD Jia Han MD, PhD Ahmed Adel Sofy MD Ahmed Saeed Ahmed MD Ahmed Taha Abdesattart MD Emmanuel Kwateng Drokow MD, PhD Kai Sun MD, PhD |
| author_sort | Hafiz Abdul Waqas Ahmed MD |
| collection | DOAJ |
| description | Eltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy (“Eltrombopag” OR “Benzoates” OR “Hydrazines”) AND (“Idiopathic Thrombocytopenic Purpura” OR “immune thrombocytopenia” OR “Idiopathic Thrombocytopenic Purpuras” OR “Immune Thrombocytopenia” OR “Autoimmune Thrombocytopenia” OR “Werlhof”). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous ( P = .27, I 2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous ( P = .001, I 2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al ( P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008). |
| first_indexed | 2024-12-24T11:17:54Z |
| format | Article |
| id | doaj.art-b62568d88ee445d19b32944ad0fde7da |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-12-24T11:17:54Z |
| publishDate | 2021-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-b62568d88ee445d19b32944ad0fde7da2022-12-21T16:58:20ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232021-04-012710.1177/10760296211005555Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-AnalysisHafiz Abdul Waqas Ahmed MD0Ahmed Taher Masoud MD1Jia Han MD, PhD2Ahmed Adel Sofy MD3Ahmed Saeed Ahmed MD4Ahmed Taha Abdesattart MD5Emmanuel Kwateng Drokow MD, PhD6Kai Sun MD, PhD7 Department of Hematology, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital Henan, Zhengzhou, People’s Republic of China Faculty of Medicine, Fayoum University, Fayoum, Egypt Kanazawa Medical University, Kanazawa, Japan Faculty of Medicine, Fayoum University, Fayoum, Egypt Faculty of Medicine, Fayoum University, Fayoum, Egypt Faculty of Medicine, Fayoum University, Fayoum, Egypt Department of Hematology, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital Henan, Zhengzhou, People’s Republic of China Department of Hematology, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital Henan, Zhengzhou, People’s Republic of ChinaEltrombopag is an orally administered, non-peptide, thrombopoietin receptor agonist which initiates thrombopoietin signaling and stimulates the production of normally functioning platelet. We aimed to do a systematic review and meta-analysis of currently available published data to verify whether eltrombopag treatment in patients with chronic immune-mediated thrombocytopenia can prolong survival. We searched for published, randomized, controlled trials in PubMed, Cochrane and Scopus databases using the following search strategy (“Eltrombopag” OR “Benzoates” OR “Hydrazines”) AND (“Idiopathic Thrombocytopenic Purpura” OR “immune thrombocytopenia” OR “Idiopathic Thrombocytopenic Purpuras” OR “Immune Thrombocytopenia” OR “Autoimmune Thrombocytopenia” OR “Werlhof”). The pooled relative risk (RR) showed that eltrombopag group has significantly higher overall platelet response than placebo group (MD = 3.42, 95% CI [2.51, 4.65], P > .0001); pooled results were homogenous ( P = .27, I 2 = 22%). The pooled relative risk showed that eltrombopag group has lower incidence of any bleeding than placebo group (MD = 0.65, 95% CI [0.48, 0.87], P = .003); pooled results were heterogenous ( P = .001, I 2 = 75%) and the detected heterogeneity was best resolved after excluding Bussel et al ( P = .10). Homogeneous results were still favored eltrombopag group (MD = 0.75, 95% CI [0.60, 0.93], P = .008).https://doi.org/10.1177/10760296211005555 |
| spellingShingle | Hafiz Abdul Waqas Ahmed MD Ahmed Taher Masoud MD Jia Han MD, PhD Ahmed Adel Sofy MD Ahmed Saeed Ahmed MD Ahmed Taha Abdesattart MD Emmanuel Kwateng Drokow MD, PhD Kai Sun MD, PhD Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis Clinical and Applied Thrombosis/Hemostasis |
| title | Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis |
| title_full | Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis |
| title_fullStr | Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis |
| title_full_unstemmed | Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis |
| title_short | Eltrombopag Effectiveness and Tolerability in Chronic Immune Thrombocytopenia: A Meta-Analysis |
| title_sort | eltrombopag effectiveness and tolerability in chronic immune thrombocytopenia a meta analysis |
| url | https://doi.org/10.1177/10760296211005555 |
| work_keys_str_mv | AT hafizabdulwaqasahmedmd eltrombopageffectivenessandtolerabilityinchronicimmunethrombocytopeniaametaanalysis AT ahmedtahermasoudmd eltrombopageffectivenessandtolerabilityinchronicimmunethrombocytopeniaametaanalysis AT jiahanmdphd eltrombopageffectivenessandtolerabilityinchronicimmunethrombocytopeniaametaanalysis AT ahmedadelsofymd eltrombopageffectivenessandtolerabilityinchronicimmunethrombocytopeniaametaanalysis AT ahmedsaeedahmedmd eltrombopageffectivenessandtolerabilityinchronicimmunethrombocytopeniaametaanalysis AT ahmedtahaabdesattartmd eltrombopageffectivenessandtolerabilityinchronicimmunethrombocytopeniaametaanalysis AT emmanuelkwatengdrokowmdphd eltrombopageffectivenessandtolerabilityinchronicimmunethrombocytopeniaametaanalysis AT kaisunmdphd eltrombopageffectivenessandtolerabilityinchronicimmunethrombocytopeniaametaanalysis |